Nuclear DUX4 immunohistochemistry is a highly sensitive and specific marker for the presence of CIC::DUX4 fusion in CIC‐rearranged sarcomas: a study of 48 molecularly confirmed cases

Rodrigo T Macedo,Vira Baranovska‐Andrigo,Tamás Pancsa,Natálie Klubíčková,Brian P Rubin,Scott E Kilpatrick,John R Goldblum,Karen J Fritchie,Steven D Billings,Michal Michal,Marián Švajdler,Zdeněk Kinkor,Michael Michal,Josephine K Dermawan

DOI: https://doi.org/10.1111/his.15341

2024-10-11

Histopathology

Abstract:DUX4 can be used as a surrogate for CIC gene rearrangements. Of 48 CIC‐rearranged sarcomas (CRS), 40 had DUX4 immunohistochemistry available and 39 had nuclear expression (sensitivity = 98%). None of the non‐CRS cases (n = 105) demonstrated this nuclear expression of DUX4 (specificity = 100%). Aims CIC‐rearranged sarcomas (CRS) are clinically aggressive undifferentiated round cell sarcomas (URCS), commonly driven by CIC::DUX4. Due to the repetitive nature of DUX4 and the variability of the fusion breakpoints, CIC::DUX4 fusion may be missed by molecular testing. Immunohistochemical (IHC) stains have been studied as surrogates for the CIC::DUX4 fusion. We aim to assess the performance of DUX4 IHC in the work‐up of CRS and its expression in non‐CRS round cell or epithelioid neoplasms. Methods and results Cases of molecularly confirmed CRS (n = 48) and non‐CRS (n = 105) were included. CRS cases consisted of 35 females and 13 males, with ages ranging from less than 1 year to 67 years (median = 41 years). Among the molecularly confirmed non‐CRS cases, C‐terminal DUX4 expression was investigated in Ewing sarcomas (38 cases), alveolar rhabdomyosarcomas (18 cases), desmoplastic small round cell tumours (12 cases) and synovial sarcomas (n = five), as well as in non‐mesenchymal neoplasms such as SMARCA4/SMARCB1‐deficient tumours (n = five), carcinomas of unknown primary (n = three) and haematolymphoid neoplasms (four cases). DUX4 IHC was considered positive when strong nuclear expression was detected in more than 50% of neoplastic cells. When used as a surrogate for the diagnosis of CRS, the sensitivity and specificity of DUX4 IHC was 98 and 100%, respectively. Only one CRS case was negative for DUX4 IHC and harboured a CIC::FOXO4 fusion. Conclusions DUX4 IHC is a highly sensitive and specific surrogate marker for the presence of CIC::DUX4 fusion, demonstrating its utility in establishing a diagnosis of CRS.

pathology,cell biology